Opinion|Videos|May 3, 2024
Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
Author(s)Ioana Preston, MD
An expert on pulmonary arterial hypertension discusses the limitations of current therapies and the barriers to early diagnosis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What are the limitations of current pulmonary arterial hypertension (PAH) therapies that primarily focus on symptom management, and how do they impact patient outcomes?
- How does the high disease burden associated with PAH affect patients' quality of life and functional status?
- What are the barriers to early diagnosis and initiation of treatment for PAH, and how do they contribute to poor outcomes?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Vutrisiran Effects Consistent With, Without Tafamidis in ATTR-CM
3
Cardiac Risks of COVID-19 Vaccine vs Infection: Eman Toraih, MD, PhD
4
The Next Frontier in Hepatitis B Functional and Virologic Cure
5